Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production
ToplineNovo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company’s weight loss and diabetes drugs Wegovy and Ozempic,